Option Care Health (NASDAQ:OPCH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Option Care Health (NASDAQ:OPCH) from a hold rating to a buy rating in a report published on Saturday.

Several other research firms have also weighed in on OPCH. TD Cowen cut their target price on shares of Option Care Health from $30.00 to $27.00 and set a “hold” rating for the company in a report on Monday, November 3rd. JMP Securities set a $36.00 price target on shares of Option Care Health in a research report on Friday, October 31st. Citizens Jmp decreased their price objective on shares of Option Care Health from $38.00 to $36.00 and set a “market outperform” rating for the company in a research report on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Option Care Health in a research note on Monday, December 29th. Finally, Citigroup restated an “outperform” rating on shares of Option Care Health in a research note on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Option Care Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.27.

Option Care Health Stock Performance

Shares of OPCH stock opened at $32.06 on Friday. Option Care Health has a 52-week low of $24.24 and a 52-week high of $35.53. The company has a quick ratio of 1.05, a current ratio of 1.56 and a debt-to-equity ratio of 0.85. The stock has a market cap of $5.09 billion, a PE ratio of 25.44, a price-to-earnings-growth ratio of 1.98 and a beta of 0.80. The business has a 50-day simple moving average of $30.83 and a 200-day simple moving average of $29.40.

Insider Buying and Selling

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 38,000 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was bought at an average cost of $25.98 per share, for a total transaction of $987,240.00. Following the purchase, the director owned 413,390 shares in the company, valued at approximately $10,739,872.20. This represents a 10.12% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.64% of the company’s stock.

Institutional Trading of Option Care Health

Institutional investors have recently made changes to their positions in the company. USA Financial Formulas acquired a new position in Option Care Health in the 2nd quarter valued at $26,000. Cornerstone Planning Group LLC raised its position in shares of Option Care Health by 7,621.4% in the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock valued at $30,000 after buying an additional 1,067 shares during the last quarter. Advisory Services Network LLC purchased a new position in shares of Option Care Health in the third quarter worth about $35,000. McIlrath & Eck LLC purchased a new position in shares of Option Care Health in the second quarter worth about $37,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Option Care Health during the third quarter worth about $38,000. 98.05% of the stock is owned by institutional investors and hedge funds.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.